ANI Pharmaceuticals (NASDAQ:ANIP) Stock

ANI PHARMACEUTICALS INC

ANI Pharmaceuticals

ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.

ANI Pharmaceuticals Inc

News

ANIP

ANI Pharmaceuticals Announced The Launch Of Nitazoxanide Tablets, 500 Mg

Nikhil Lalwani, President and CEO of ANI stated, "This transaction reflects our commitment to strengthening our Retina portfolio and maximizing the long-term value of ILUVIEN and YUTIQ. By eliminating this royalty obligation, we have enhanced our financial flexibility and ability to accelerate growth as we pursue our purpose of ‘Serving Patients, Improving Lives.'"

Health Care

General

ANI Pharmaceuticals Completed The Buyout Of Its 3.125% Perpetual Royalty Obligation To SWK Funding On Worldwide Net Revenues Of Iluvien And Yutiq For A One-time Payment Of $17.25M

HC Wainwright &amp; Co. analyst Oren Livnat reiterates ANI Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIP#NASDAQ">ANIP</a>) with a Buy and maintains $94 price target.

Price Target

Reiteration

Analyst Ratings

HC Wainwright & Co. Reiterates Buy on ANI Pharmaceuticals, Maintains $94 Price Target

4 analysts have expressed a variety of opinions on ANI Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIP#NASDAQ">ANIP</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for ANI Pharmaceuticals, presenting an average target of $86.25, a high estimate of $94.00, and a low estimate of $80.00. This current average represents a 3.09% decrease from the previous average price target of $89.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1741960857_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The standing of ANI Pharmaceuticals among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glen Santangelo</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Buy</td>
<td>$80.00</td>
<td>-</td>
</tr>
<tr>
<td>Ekaterina Knyazkova</td>
<td>JP Morgan</td>
<td>Announces</td>
<td>Overweight</td>
<td>$85.00</td>
<td>-</td>
</tr>
<tr>
<td>Vamil Divan</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$86.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Oren Livnat</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$94.00</td>
<td>$94.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to ANI Pharmaceuticals. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of ANI Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of ANI Pharmaceuticals's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of ANI Pharmaceuticals's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ANIP/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on ANI Pharmaceuticals analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Delving into ANI Pharmaceuticals's Background</h2>
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.
<h3>A Deep Dive into ANI Pharmaceuticals's Financials</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: ANI Pharmaceuticals's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 44.75%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: ANI Pharmaceuticals's net margin is impressive, surpassing industry averages. With a net margin of -5.61%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): ANI Pharmaceuticals's ROE excels beyond industry benchmarks, reaching -2.64%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): ANI Pharmaceuticals's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -0.83%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 1.55, ANI Pharmaceuticals adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: What Are They?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Outlook: ANI Pharmaceuticals Through The Eyes Of 4 Analysts

Jefferies analyst Glen Santangelo initiates coverage on ANI Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIP#NASDAQ">ANIP</a>) with a Buy rating and announces Price Target of $80.

Initiation

Jefferies Initiates Coverage On ANI Pharmaceuticals with Buy Rating, Announces Price Target of $80

The expanded label for ILUVIEN (fluocinolone acetonide intravitreal implant) includes an indication for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye (NIU-PS).&nbsp;
The approval also includes other updates to the label including to the Warnings and Precautions section.&nbsp;
As previously announced, the Company plans to market ILUVIEN for chronic NIU-PS in addition to its current indication of diabetic macular edema (DME) in the U.S. ILUVIEN is already approved for both DME and NIU-PS outside the U.S., including in seventeen European countries.

ANI Pharmaceuticals Says FDA Approved Expanded Label For ILUVIEN

JP Morgan analyst Ekaterina Knyazkova initiates coverage on ANI Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIP#NASDAQ">ANIP</a>) with a Overweight rating and announces Price Target of $85.

JP Morgan Initiates Coverage On ANI Pharmaceuticals with Overweight Rating, Announces Price Target of $85

Guggenheim analyst Vamil Divan maintains ANI Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIP#NASDAQ">ANIP</a>) with a Buy and raises the price target from $84 to $86.

Guggenheim Maintains Buy on ANI Pharmaceuticals, Raises Price Target to $86

This new presentation will be available in 40 USP units/0.5 mL and 80 USP units/mL single-dose options through Cortrophin Gel's established specialty pharmacy network.

ANI Pharmaceuticals Secures FDA Approval Of Purified Cortrophin Gel (Repository Corticotropin Injection USP) In Prefilled Syringe Format

On Friday, ANI Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIP#NASDAQ">ANIP</a>) reported fourth-quarter adjusted EPS of $1.63, up from $1 a year ago, beating the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $1.44</a>.
The company reported sales of $190.57 million, up 44.8% year over year, beating the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g44038542/ani-pharmaceuticals-reports-record-fourth-quarter-and-full-year-2024-financial-results-and-raises-" rel="noreferrer noopener">consensus of $175.37 million</a>.
On an organic basis, excluding the acquisition of Alimera, total net revenues grew 23.8% year-over-year.
Net revenues for rare diseases, which include Cortrophin Gel, Iluvien, and Yutiq, increased by 108.5% to $87.0 million.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41296581/ani-pharmaceuticals-shifts-focus-from-generics-to-high-margin-brand-assets-analyst-" rel="noreferrer noopener">ANI Pharmaceuticals Shifts Focus From Generics To High-Margin Brand Assets, Analyst Sees Strong Potential</a>
Cortrophin Gel net revenues increased 42.3% to $59.4 million, driven by increased volume.
Iluvien and Yutiq generated net revenues of $27.6 million in the first full quarter <a target="_blank" href="https://www.benzinga.com/general/biotech/24/06/39460281/generics-player-ani-pharmaceuticals-strengthens-rare-disease-segment-with-380m-alimera-sciences-d" rel="noreferrer noopener">following the acquisition of Alimera</a>.
Net revenues for Brands increased 58.9% to $19.8 million, driven by increased demand.
Net revenues for Generic pharmaceutical products increased 9.4% to $78.6 million, driven by increased volumes in the base business and the contribution from new product launches.
The company launched five new products during the quarter and 17 for the full year. ANI&#8217;s strong R&amp;D and commercial productivity continued into the first quarter of 2025 with the launch of Prucalopride Tablets with 180 days of exclusivity.
The company says momentum has continued in the first quarter of 2025, with the number of new cases initiated reaching a new high in February.
Brands&#8217; revenues increased 58.9% to $19.8 million, driven by increased demand for certain products, which has occurred periodically over the past two years.
While this additional demand has persisted into the first quarter of 2025, the company anticipates a normalized performance thereafter for the purpose of full-year 2025 guidance.
Guidance: ANI Pharmaceuticals expects 2025 revenues of $756 million—$776 million, versus prior guidance of $739 million—$759 million and a consensus of $724.71 million.
The company expects adjusted EBITDA of $190 million-$200 million compared to prior guidance of $182 million-$192 million.
&#8220;With our business off to a strong start in 2025, particularly Cortrophin Gel, Generics, and Brands, we are raising our 2025 guidance for total net revenues and adjusted non-GAAP EBITDA,&#8221; said Nikhil Lalwani, President and CEO.
ANI Pharmaceuticals expects 2025 adjusted EPS of $6.12-$6.49 versus a consensus of $5.56.
Price Action: ANIP stock is up 10.41% at $60.26 at the last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/25/02/44043253/mplx-seals-715-million-deal-for-full-control-of-bangl-pipeline-details" target="_blank" rel="noreferrer noopener">MPLX Seals $715 Million Deal For Full Control Of BANGL Pipeline: Details</a></li>
</ul>
Image via Shutterstock

Earnings

Guidance

Movers

Trading Ideas

ANI Pharmaceuticals Expects Strong Start To 2025, On Back Of Cortrophin Gel And Generics, Lifts Annual Forecast

WIIM

ANI Pharmaceuticals shares are trading higher after the company reported better-than-expected Q4 financial results.

ANI Pharmaceuticals Expects 2025 Adjusted EPS Of $6.12-$6.49 Versus Consensus Of $5.56

<figure class="table"> 
<table>
<tbody>
<tr>
<td>Revised Full Year 2025 Guidance:</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>&nbsp;</td>
<td>Full Year 2025 Guidance</td>
<td>Previous Full Year 2025 Guidance</td>
<td>2024 Actual</td>
<td>Growth</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Net Revenue (Total Company)</td>
<td>$756 million - $776 million</td>
<td>$739 million - $759 million</td>
<td>$614 million</td>
<td>23% - 26%</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Cortrophin Gel Net Revenue</td>
<td>$265 million - $274 million</td>
<td>n/p</td>
<td>$198 million</td>
<td>34% - 38%</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>ILUVIEN and YUTIQ Net Revenue</td>
<td>$97 million - $103 million</td>
<td>n/p</td>
<td>$32 million</td>
<td>n/m</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Adjusted Non-GAAP EBITDA</td>
<td>$190 million - $200 million</td>
<td>$182 million - $192 million</td>
<td>$156 million</td>
<td>22% - 28%</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Adjusted Non-GAAP Diluted EPS</td>
<td>$6.12 - $6.49</td>
<td>n/p</td>
<td>$5.20</td>
<td>18% - 25%</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
</tbody>
</table>
</figure>

ANI Pharmaceuticals Expects 2025 Revenues Of $756M-$776M Versus Prior Guidance Of $739M-$759M And Consensus Of $724.71M, With Adjusted EBITDA Of $190M-$200M Compared To Prior Guidance Of $182M-$192M

ANI Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIP#NASDAQ">ANIP</a>) reported quarterly earnings of $1.63 per share which beat the analyst consensus estimate of $1.44 by 13.19 percent. This is a 63 percent increase over earnings of $1.00 per share from the same period last year. The company reported quarterly sales of $190.57 million which beat the analyst consensus estimate of $175.37 million by 8.67 percent. This is a 44.75 percent increase over sales of $131.65 million the same period last year.

ANI Pharmaceuticals Q4 2024 Adj EPS $1.63 Beats $1.44 Estimate, Sales $190.57M Beat $175.37M Estimate

<h3>Companies Reporting Before The Bell</h3>
• Frontline (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FRO#NYSE">FRO</a>) is estimated to report quarterly earnings at $0.27 per share on revenue of $282.62 million. 
• Nordic American Tankers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NAT#NYSE">NAT</a>) is estimated to report quarterly earnings at $0.04 per share on revenue of $53.07 million. 
• Fluent (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLNT#NASDAQ">FLNT</a>) is estimated to report quarterly loss at $0.23 per share on revenue of $68.06 million. 
• Recursion Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>) is expected to report quarterly loss at $0.41 per share on revenue of $18.17 million. 
• Oxford Square Cap (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OXSQ#NASDAQ">OXSQ</a>) is projected to report quarterly earnings at $0.06 per share on revenue of $9.90 million. 
• Integral Ad Science (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IAS#NASDAQ">IAS</a>) is estimated to report quarterly earnings at $0.25 per share on revenue of $148.94 million. 
• PAR Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAR#NYSE">PAR</a>) is estimated to report quarterly loss at $0.08 per share on revenue of $99.26 million. 
• ANI Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIP#NASDAQ">ANIP</a>) is expected to report quarterly earnings at $0.31 per share on revenue of $175.12 million. 
• TeraWulf (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WULF#NASDAQ">WULF</a>) is estimated to report quarterly loss at $0.02 per share on revenue of $37.36 million. 
• Global Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLP#NYSE">GLP</a>) is estimated to report quarterly earnings at $0.90 per share on revenue of $5.80 billion. 
• Rapid Micro Biosystems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPID#NASDAQ">RPID</a>) is expected to report quarterly loss at $0.22 per share on revenue of $7.60 million. 
• FuboTV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FUBO#NYSE">FUBO</a>) is estimated to report quarterly loss at $0.11 per share on revenue of $444.91 million. 
• Butterfly Network (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFLY#NYSE">BFLY</a>) is expected to report quarterly loss at $0.08 per share on revenue of $21.01 million. 
• Natural Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRP#NYSE">NRP</a>) is projected to report earnings for its fourth quarter. 
• Apellis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) is expected to report quarterly loss at $0.37 per share on revenue of $191.93 million. 
• Calumet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLMT#NASDAQ">CLMT</a>) is estimated to report quarterly loss at $0.36 per share on revenue of $929.11 million. 
• 1stdibs.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DIBS#NASDAQ">DIBS</a>) is estimated to report quarterly earnings at $0.00 per share on revenue of $22.02 million. 
• LandBridge (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LB#NYSE">LB</a>) is projected to report quarterly earnings at $0.78 per share on revenue of $244.81 million. 
• Fulgent Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLGT#NASDAQ">FLGT</a>) is estimated to report quarterly loss at $0.37 per share on revenue of $75.39 million. 
• Owens &amp; Minor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMI#NYSE">OMI</a>) is estimated to report quarterly earnings at $0.53 per share on revenue of $2.73 billion. 
• Amneal Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRX#NASDAQ">AMRX</a>) is projected to report quarterly earnings at $0.15 per share on revenue of $700.83 million. 
• Banco Latinoamericano (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLX#NYSE">BLX</a>) is likely to report quarterly earnings at $0.44 per share on revenue of $251.03 million. 
• Chart Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GTLS#NYSE">GTLS</a>) is expected to report quarterly earnings at $3.23 per share on revenue of $1.18 billion. 
• Alpha Metallurgical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMR#NYSE">AMR</a>) is estimated to report quarterly earnings at $1.12 per share on revenue of $683.10 million. 
• Docebo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCBO#NASDAQ">DCBO</a>) is expected to report quarterly earnings at $0.27 per share on revenue of $56.24 million. 
• Northwest Natural Hldg (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NWN#NYSE">NWN</a>) is expected to report quarterly earnings at $1.49 per share on revenue of $395.05 million. 
<h3>Companies Reporting After The Bell</h3>
• BIT Mining (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BTCM#NYSE">BTCM</a>) is estimated to report earnings for its fourth quarter. 
• Monroe Cap (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRCC#NASDAQ">MRCC</a>) is expected to report quarterly earnings at $0.27 per share on revenue of $14.99 million. 
• Longeveron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGVN#NASDAQ">LGVN</a>) is projected to report quarterly loss at $0.36 per share on revenue of $660 thousand. 
• Middlesex Water (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSEX#NASDAQ">MSEX</a>) is likely to report quarterly earnings at $0.37 per share on revenue of $45.00 million. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMRX

APLS

BFLY

BTCM

CLMT

DCBO

DIBS

FLGT

FLNT

FUBO

GTLS

LGVN

MRCC

MSEX

OXSQ

RPID

RXRX

WULF

Earnings Scheduled For February 28, 2025

U.S. stock futures were higher this morning, with the Dow futures gaining around 0.1% on Thursday.
Shares of Southwest Airlines Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUV#NYSE">LUV</a>) fell sharply in today's <a href="https://www.benzinga.com/government/regulations/25/01/43017875/southwest-airlines-is-sued-by-department-of-transportation-over-chronically-delayed-flights">pre-market trading</a>.
The U.S. Department of Transportation and Department of Justice jointly filed a lawsuit on Wednesday against Southwest Airlines for operating &#8220;chronically delayed flights&#8221; that caused disruptions to passengers.
Southwest Airlines shares fell 3% to $31.83 in pre-market trading
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>Transcontinental Realty Investors, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TCI#NYSE">TCI</a>) shares dipped 31.8% to $19.01 in pre-market trading.</li>
<li>C&amp;F Financial Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CFFI#NASDAQ">CFFI</a>) shares declined 15.3% to $60.01 in pre-market trading.</li>
<li>SI-BONE, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIBN#NASDAQ">SIBN</a>) fell 14.7% to $14.01 in pre-market trading after gaining 5% on Wednesday. SI-BONE recently reported preliminary fourth-quarter revenue results.</li>
<li>Radiant Logistics, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RLGT#NYSE">RLGT</a>) shares tumbled 13.8% to $6.03 in pre-market trading.</li>
<li>ANI Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIP#NASDAQ">ANIP</a>) shares tumbled 11.6% to $50.01 in pre-market trading. ANI Pharmaceuticals recently issued preliminary fourth quarter and 2024 financial results and preliminary 2025 outlook.</li>
<li>Silexion Therapeutics Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLXN#NASDAQ">SLXN</a>) fell 11.3% to $1.38 in pre-market trading after the company announced the pricing of $5.0 million public offering.</li>
<li>Unisys Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UIS#NYSE">UIS</a>) dipped 8.9% to $6.03 in pre-market trading.</li>
<li>NewAmsterdam Pharma Company N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAMS#NASDAQ">NAMS</a>) declined 5.6% to $22.66 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/01/42998360/wall-streets-most-accurate-analysts-give-their-take-on-3-defensive-stocks-delivering-high-dividend-yields-2">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Defensive Stocks Delivering High-Dividend Yields</a></li>
</ul>

Pre-Market Outlook

Markets

CFFI

NAMS

RLGT

SIBN

SLXN

Southwest Airlines, Silexion Therapeutics And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

Shares of Taiwan Semiconductor Manufacturing Company Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) rose sharply in today's pre-market trading after the company announced <a href="https://www.benzinga.com/quote/TSM">fourth-quarter results</a>.
Taiwan Semiconductor Mfg. said net profit climbed 57% year-over-year to a record T$374.68 billion ($11.38 billion).
TSMC shares gained 4.7% to $216.61 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>SOBR Safe, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOBR#NASDAQ">SOBR</a>) gained 83.1% to $1.63 in pre-market trading after gaining 8% on Wednesday.</li>
<li>Powell Max Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PMAX#NASDAQ">PMAX</a>) gained 67.8% to $2.45 in pre-market trading after the company announced acquisition plans and is targeting firms with between $1 million and $5 million in revenue to expand into the Hong Kong and Asian financial communications market.</li>
<li>BioLineRx Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLRX#NASDAQ">BLRX</a>) rose 40.1% to $0.1458 in pre-market trading after dipping 15% on Wednesday. BioLineRx recently announced a $10 million registered direct offering.</li>
<li>Wheeler Real Estate Investment Trust, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WHLR#NASDAQ">WHLR</a>) gained 39.3% to $3.28 in pre-market trading after falling 4% on Wednesday.</li>
<li>AEON Biopharma, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEON#NYSE">AEON</a>) rose 22.5% to $0.1342 in pre-market trading after dipping 14% on Wednesday. AEON Biopharma recently announced closing of $20.0 million underwritten public offering</li>
<li>DouYu International Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOYU#NASDAQ">DOYU</a>) rose 17.4% to $14.43 in pre-market trading after the company named Ms. Simin Ren as co-CEO and announced a special cash dividend of $9.94/ADS.</li>
<li>BigBear.ai Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBAI#NYSE">BBAI</a>) gained 15.1% to $3.90 in pre-market trading after the company announced a chief executive transition. BigBear.ai has appointed Kevin McAleenan as CEO and a member of the company's board, effective as of Wednesday. McAleenan will replace Mandy Long, who is transitioning to an advisory role.</li>
<li>Tonix Pharmaceuticals Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) gained 12.8% to $0.2620 in pre-market trading.</li>
<li>Quantum Computing Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUBT#NASDAQ">QUBT</a>) gained 10.3% to $12.74 in pre-market trading after surging 55% on Wednesday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Transcontinental Realty Investors, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TCI#NYSE">TCI</a>) shares fell 31.8% to $19.01 in pre-market trading.</li>
<li>Algorhythm Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIME#NASDAQ">RIME</a>) fell 20.3% to $0.04 in pre-market trading after dipping 35% on Wednesday.</li>
<li>GlucoTrack, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCTK#NASDAQ">GCTK</a>) dipped 20.3% to $0.0630 in pre-market trading following a 35% decline on Wednesday.</li>
<li>Sonim Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONM#NASDAQ">SONM</a>) declined 15.5% to $3.19 in pre-market trading. Sonim Technologies shares gained 10% on Wednesday after Orbic North America announced an agreement in principle to acquire a substantial equity ownership position in the company.</li>
<li>C&amp;F Financial Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CFFI#NASDAQ">CFFI</a>) shares fell 15.3% to $60.01 in pre-market trading.</li>
<li>SI-BONE, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIBN#NASDAQ">SIBN</a>) fell 14.7% to $14.01 in pre-market trading after gaining 5% on Wednesday. SI-BONE recently reported preliminary fourth-quarter revenue results.</li>
<li>LuxUrban Hotels Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUXH#NASDAQ">LUXH</a>) shares dipped 12.9% to $0.5991 in pre-market trading. LuxUrban Hotels recently issued FY25 revenue guidance.</li>
<li>Sangoma Technologies Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SANG#NASDAQ">SANG</a>) fell 12.1% to $6.19 in today's pre-market trading after gaining 5% on Wednesday.</li>
<li>ANI Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIP#NASDAQ">ANIP</a>) shares tumbled 11.6% to $50.01 in pre-market trading. ANI Pharmaceuticals recently issued preliminary fourth quarter and 2024 financial results and preliminary 2025 outlook.</li>
<li>Silexion Therapeutics Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLXN#NASDAQ">SLXN</a>) fell 11.3% to $1.38 in pre-market trading after the company announced the pricing of $5.0 million public offering.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/01/42998360/wall-streets-most-accurate-analysts-give-their-take-on-3-defensive-stocks-delivering-high-dividend-yields-2">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Defensive Stocks Delivering High-Dividend Yields</a></li>
</ul>

AEON

BBAI

BLRX

DOYU

GCTK

LUXH

PMAX

QUBT

RIME

SANG

SOBR

SONM

TNXP

WHLR

Why Taiwan Semiconductor Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket

Long time industry leader, Chairman of the Board Patrick Walsh replaces CEO Bill Humphries&nbsp;
DURHAM, N.C., Jan. 13, 2025 /PRNewswire/ -- Alcami Corporation ("Alcami"), a leading contract development and manufacturing organization (CDMO), today announced the resignation of Bill Humphries. Alcami's Board Chair and former Chief Executive Officer Patrick Walsh will serve as Interim CEO, ensuring the continuation of smooth operations and a strong client-centric approach from a proven industry veteran.

Management

Alcami Announces Bill Humphries To Retire; Board Chair And Former Chief Executive Officer Patrick Walsh Will Serve As Interim CEO

Preliminary Fourth Quarter and Full Year 2024 Financial Results
Based on preliminary, unaudited results, ANI expects Purified Cortrophin Gel net revenues of $59.2 million to $59.8 million for the fourth quarter of 2024 and $197.8 million to $198.4 million for the full year 2024. In addition, the company expects combined ILUVIEN and YUTIQ net revenues of $26.6 million to $27.2 million for the fourth quarter of 2024 and $30.4 million to $31.0 million for the post-acquisition period from September 16, 2024 to December 31, 2024.
Additionally, the Company expects full year 2024 total net revenues, adjusted non-GAAP EBITDA, and adjusted non-GAAP diluted EPS to be at or above the guidance ranges provided on November 8, 2024.
The information presented above is unaudited and reflects preliminary estimates subject to the completion of financial closing procedures and any adjustments that may result from the finalization of the quarterly and annual review of the Company's consolidated financial statements. ANI will report its full year 2024 results during its fourth quarter 2024 earnings conference call in late February.
Preliminary Full Year 2025 Outlook
For full year 2025, ANI expects total net revenues of between $739 million and $759 million, representing growth of 24% to 27% as compared to the midpoint of 2024 guidance, and adjusted non-GAAP EBITDA of between $182 million and $192 million.
ANI will provide its full 2025 financial guidance during its fourth quarter 2024 earnings conference call in late February.

ANI Pharma Expects Q4 Purified Cortrophin Gel Revenues of $59.2M-$59.8M And $197.8M-$198.4M For FY24, Q4 ILUVIEN And YUTIQ Revenues Of $26.6M-$27.2M, FY25 Total Revenue Of $739M-$759M

Press Releases

Alcami Announces CEO Transition

ANI Pharmaceuticals to Present at the Guggenheim Biotech Conference

ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2024 Financial Results on February 28, 2025, at 8:00 a.m. ET

ANI Pharmaceuticals to Present at Raymond James' Institutional Investors and Leerink Partners Global Healthcare Conferences in March

ANI Pharmaceuticals Reports Record Fourth Quarter and Full-Year 2024 Financial Results and Raises 2025 Guidance

ANI Pharmaceuticals Announces FDA Approval of New Purified Cortrophin Gel® Prefilled Syringe

ANI Pharmaceuticals Announces FDA Approval for Expansion of ILUVIEN® Label

Contracts

ANI Pharmaceuticals Announces Buyout of Royalty Obligation for ILUVIEN® and YUTIQ®

ANI Pharmaceuticals Announces the Launch of Nitazoxanide Tablets

ANI Pharmaceuticals to Present at 2025 RBC Capital Markets Ophthalmology Virtual Conference

Comments

ANI Pharmaceuticals

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL